Relapsed CLL: ASCO Tumor Boards

This is a case-based activity that includes a discussion of a 67-year-old man diagnosed with CLL after presenting with fatigue, 20lb weight loss, and diffuse lymphadenopathy. His prognostic markers were deletion 13q and unmutated IgHV. Past medical history was significant for aortic dissection which was surgically repaired with insertion of a mechanical valve 8 years prior. He had been on warfarin for anticoagulation since the surgery. He was later diagnosed with paroxysmal atrial fibrillation which had been rate controlled with carvedilol. Two years later, his CLL relapsed with increasing lymphocyte count and generalized lymphadenopathy.

At the end of this course, learners should be able to:

  • Evaluate relevant disease and patient factors to inform treatment choice for a patient with CLL.
  • Appreciate unique considerations in the assessment of older patients with CLL.
  • Evaluate the role of targeted agents and combined modality regimens in the treatment of relapsed CLL.
  • Identify key side effects of targeted agents and apply appropriate supportive care measures.
  • Compare efficacy and toxicity of chemoimmunotherapy vs. targeted agents in specific patient populations.

Continuing Education Credit: 1.5 Credits/Points are available for participation in this course. Certificate and credit types include:

  • AMA PRA Category 1 Credits
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Note: This course expires on September 19, 2020. Learners must complete all necessary course components by this date. This course is available